Receiver operating characteristic curve analysis has shown that BACE1-AS levels can be used to discriminate among pre-AD, full-AD, and healthy control samples with high sensitivity and specificity, thereby highlighting its potential utility as a biomarker for AD progression and diagnosis (Fotuhi et al., 2019). This evidence concerns the gene BACE1 and Alzheimer disease.